Specific Drug Delivery to Cancer Cells with Double-Imprinted Nanoparticles against Epidermal Growth Factor Receptor
2018 · Nano Letters · 162 citations
https://doi.org/10.1021/acs.nanolett.7b03206
L
Larissa Lezina
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
22
Papers
1.3K
Citations
16
h-index
19
i10-index
Larissa Lezina is an academic researcher from Nazarbayev University. The author has contributed to research in topics: Epigenetics and DNA Methylation & Cancer-related Molecular Pathways & Lymphoma Diagnosis and Treatment. The author has an h-index of 16, co-authored 19 publications.
ORCID: 0009-0002-8580-1327Papers by this author
worksmiR-16 and miR-26a target checkpoint kinases Wee1 and Chk1 in response to p53 activation by genotoxic stress
2013 · Cell Death and Disease · 80 citations
https://doi.org/10.1038/cddis.2013.483
GSK137, a potent small-molecule BCL6 inhibitor with in vivo activity, suppresses antibody responses in mice
2021 · Journal of Biological Chemistry · 22 citations
https://doi.org/10.1016/j.jbc.2021.100928
Modulation of EGFR Activity by Molecularly Imprinted Polymer Nanoparticles Targeting Intracellular Epitopes
2023 · Nano Letters · 16 citations
https://doi.org/10.1021/acs.nanolett.3c01374
An optimised patient-derived explant platform for breast cancer reflects clinical responses to chemotherapy and antibody-directed therapy
2024 · Scientific Reports · 9 citations
https://doi.org/10.1038/s41598-024-63170-0
T86
2015 · European Journal of Cancer Supplements · 1 citations
https://doi.org/10.1016/j.ejcsup.2015.08.006
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat